Lowe M.N. & Lamb H.M.
Meropenem – An updated Review of its use in the Management of Intra-Abdominal Infections
Drugs, Sept 2000; 60 : 619-646
Meropenem is a carbapenem antibacterial agent with a broad spectrum of activity which encompasses Gram negative, Gram positive and anaerobic bacteria. It is resistant to beta lactamases.
In patients with moderate to severe intra-abdominal infections, empirical monotherapy with meropenem achieved clinical response rates ranging from 91% to 100% in 7 randomised comparative trials.
Early Inhaled Glucocorticoid Therapy to Prevent Bronchopulmonary Dysplasia
Cole CH, Colton T, Shah BL, et al (Tufts Univ, Boston; Boston Univ; Pensylvania Hosp, Philadelphia)
N Engl J Med 340: 1005- 1010, 1999
Bronchopulmonary dysplasia (BPD) is a disease seen in premature babies. Inflammatory mediator cytokine plays a key role in its development following prenatal or postnatal sepsis. The current treatment for BPD is the use of systemic steroids and mechanical ventilation.
The present study evaluated the role of inhaled beclomethasone in neonates with BPD. The study concluded that early therapy with inhaled beclomethasone did not significantly alter the incidence of BPD at 28 days of age or at 36 weeks of gestational age. However with the use of inhaled beclomethasone requirement for systemic glucocorticoids and bronchodilator therapy decreased significantly. Also at 28 days, fewer patients receiving inhaled beclomethasone still required mechanical ventilation.
Thus inhaled steroids started in the first 2 weeks of life does not prevent BPD but like systemic steroids, does reduce the need for & duration of mechanical ventilation.